Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoproliferative Disease: early-phase trial registry
1 of 2 indexed Lymphoproliferative Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Lymphoproliferative Disease: 2 US clinical trials tracked, 1 recruiting.
Lymphoproliferative Disease is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition lymphoproliferative-disease
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Lymphoproliferative Disease lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoproliferative Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoproliferative Disease is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Baylor College of Medicine
NCT01555892
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
University of California, San Francisco
NCT00516152
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoproliferative Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoproliferative Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoproliferative Disease page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lymphoproliferative Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Lymphoproliferative Disease trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoproliferative Disease condition card totals 2 registered trials; most-linked intervention Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.